Authors

Artificial Intelligence Makes Possible a Multiomic Approach in Oncology Drug Discovery

While challenges remain, AI is accelerating the process by enabling researchers to identify and design new drug candidates more quickly and efficiently with applications in target discovery, structure prediction, and drug optimization.

Using AI to Predict Launch Success

How to maximize market-entry performance for new pharma products in an increasingly competitive launch environment.

China’s Trial Advantage: Tracking Nation’s Growth in Pharma Innovation and Global Investment

A look at China's emergence as a hub for novel treatment pursuits—and ways international investors can best capitalize on the favorable research trajectory.

Stop Losing Patients at the Gate: The 24-Hour Window That Makes or Breaks Your Entire Hub Program

Pharmaceutical Commercialization: A 2026 Outlook Personalization and Precision Will Define a New Year in Pharma

Going Beyond Compliance: Early Adoption of FDA’s Quality Management Maturity Program—and the Practical Considerations for Executives

An examination of proactive preparedness and readiness review for future enrollment in the agency’s QMM program—now in the pilot stage as an effort to incentivize pharma manufacturers to achieve a more mature state of quality culture.

Point of Care Lifts Reps Efforts

Point of Care and PatientPoint can improve the impact that your Pharma Reps are already having.

Realtime Electronic Data Capture at Investigator Sites: Laboratory Data and Beyond

2025 Pharma Forecast: Four Pivotal Trends Revolutionizing Market Access Strategies

From Blockbusters to Black Holes: Pharma Launch Strategy in the Age of Technology and AI

A Brave New World: Implications of the IRA on Brand Strategy

Amid converging pharma pricing trends, such as those triggered by the Inflation Reduction Act, companies must adopt novel operational practices and strategic approaches in line with new parameters for success across a product’s lifecycle.

The Evolution of Healthcare Communication: Bridging the HCP-Patient Divide

Key trends in healthcare communication to build trust between healthcare providers and their patients.

HEOR: From Proving Product Value to Proving Its Own Worth

The recent shift in Health Economics and Outcomes Research functions across major pharmaceutical companies highlights a lack of understanding of its value.

Strategic advantage: Optichannel engagement drives ROI across the product lifecycle

Korea and Australia's P&MA Shift: From Local Launch Opportunities to Regional Blueprint

Recent policy shifts in these two influential health technology assessment markets signal a broader regional move toward faster, more innovation-friendly access frameworks.

Navigating Cross-Border Pharma Deals: Key Trends and Lessons Out of China

The importance of a strategic approach and proper due diligence in unlocking the full potential of these arrangements.

Transforming Life Sciences R&D: The Business Case for AI

Webinar Date/Time: Thu, Aug 14, 2025 3:30 PM EDT

Going Beyond Compliance: Early Adoption of FDA’s Quality Management Maturity Program—and the Practical Considerations for Executives

An examination of proactive preparedness and readiness review for future enrollment in the agency’s QMM program—now in the pilot stage as an effort to incentivize pharma manufacturers to achieve a more mature state of quality culture.

HEOR: From Proving Product Value to Proving Its Own Worth

The recent shift in Health Economics and Outcomes Research functions across major pharmaceutical companies highlights a lack of understanding of its value.

Navigating the EU’s Joint Clinical Assessment

Pathways to success for this key component of Europe’s new HTA regulation, where thinking beyond the purely technical will be critical.

From Blockbusters to Black Holes: Pharma Launch Strategy in the Age of Technology and AI

Pharma Forecasting: Key Markets Investors Can’t Ignore

The importance of expanding your pharma sales forecasting horizon beyond the US. Learn how to effectively navigate country-specific regulatory red flags.

Driving Field Excellence with AI-Enhanced Rep Support

The Situation We Faced: Risk Assessment of Failure Modes and Partners Understanding of Risk in Fill-Finish

Explore CEO insights on decision-making in manufacturing, focusing on risk management, packaging challenges, and strategies for product safety and quality.

FDA Approves Breyanzi for Adults with Relapsed or Refractory Marginal Zone Lymphoma

FDA’s approval of Bristol Myers Squibb’s Breyanzi as the first CAR T therapy for relapsed or refractory marginal zone lymphoma underscores the therapy’s expanding leadership in B-cell malignancies, backed by compelling Phase II data

AI-Enabled Benchmarking: Transforming Performance Measurement for Pharma Brands

Market dynamics boost the need and urgency for more sophisticated benchmarking strategies.

Driving Field Excellence with AI-Enhanced Rep Support

Are DTC Programs Treating a Symptom or Cause of High Drug Prices?

Jesse Mendelsohn, executive vice president at Model N, discusses the broader issues impacting drug prices.

Abu Dhabi Reinforces Global Leadership in Healthcare Innovation with High-Level US Visit

During a high-level US visit, the Department of Health—Abu Dhabi signed strategic agreements with Abbott, Boehringer Ingelheim, and Sanofi to boost pharmaceutical manufacturing, expand vaccine development, and advance digital health and clinical research.

How Pharma’s Checks and Balances Can Help Fight Its Public Perception

What can we do to prevent such blatant black eyes to the industry so many of us love?